Short- and Mid-Term Outcomes of Early Alcohol Septal Ablation Therapy for Patients with Mildly Symptomatic Hypertrophic Obstructive Cardiomyopathy: A Tertiary Center Experience.
Veysel OktayArslan SukruMuhammed Heja GecitZubeyir BulatMehmet Emin GokcePublished in: Journal of clinical medicine (2024)
Background: Left ventricular outflow tract obstruction (LVOTO) impairs survival and diminishes quality of life in patients with hypertrophic obstructive cardiomyopathy (HOCM). In this study, we aimed to investigate the safety and the efficacy of earlier alcohol septal ablation (ASA) in patients with HOCM. Methods: A total of 47 patients with mildly symptomatic HOCM (NYHA II) and having poor functional capacity despite maximal tolerated medical therapy were included. Results: The mean age of the patients was 55 ± 14, and 57% of the patients were male. All clinical endpoint targets including 30 d mortality (1% vs. 0% p < 0.01), 30 d adverse complications (10% vs. 0% p < 0.01), 30 d complete heart block resulting in need for permanent pacemaker (10% vs. 4.2% p < 0.01), more than moderate residual mitral regurgitation (5% vs. 2.1% p < 0.01), repeat procedure rate (10% vs. 4.2% p < 0.01), improvement of (NYHA) class (90% vs. 95.7% p < 0.01), rest and provoked (LVOT) gradient < 50 mmHg (90% vs. 97.8% p < 0.01) were significantly reached. Conclusions: In patients with mildly symptomatic HOCM (NYHA II), earlier ASA may be performed as an effective and safe procedure in experienced centers.
Keyphrases
- end stage renal disease
- heart failure
- chronic kidney disease
- newly diagnosed
- left ventricular
- ejection fraction
- healthcare
- peritoneal dialysis
- prognostic factors
- type diabetes
- stem cells
- hypertrophic cardiomyopathy
- risk factors
- cardiovascular disease
- metabolic syndrome
- resistance training
- patient reported outcomes
- aortic valve
- high intensity
- transcatheter aortic valve replacement
- alcohol consumption
- insulin resistance
- aortic stenosis
- adverse drug